Journal Article

DKFZ-2021-02250

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Germline determinants of humoral immune response to HPV-16 protect against oropharyngeal cancer.

Ferreiro-Iglesias, A. ; McKay, J. D. ; Brenner, N.DKFZ* ; Virani, S. ; Lesseur, C. ; Gaborieau, V. ; Ness, A. R. ; Hung, R. J. ; Liu, G. ; Diergaarde, B. ; Olshan, A. F. ; Hayes, N. ; Weissler, M. C. ; Schroeder, L.DKFZ* ; Bender, N.DKFZ* ; Pawlita, M.DKFZ* ; Thomas, S. ; Pring, M. ; Dudding, T. ; Kanterewicz, B. ; Ferris, R. ; Thomas, S. ; Brhane, Y. ; Díez-Obrero, V. ; Milojevic, M. ; Smith-Byrne, K. ; Mariosa, D. ; Johansson, M. J. ; Herrero, R. ; Boccia, S. ; Cadoni, G. ; Lacko, M. ; Holcátová, I. ; Ahrens, W. ; Lagiou, P. ; Lagiou, A. ; Polesel, J. ; Simonato, L. ; Merletti, F. ; Healy, C. M. ; Hansen, B. T. ; Nygård, M. ; Conway, D. I. ; Wright, S. ; Macfarlane, T. V. ; Robinson, M. ; Alemany, L. ; Agudo, A. ; Znaor, A. ; Amos, C. I. ; Waterboer, T. (Last author)DKFZ* ; Brennan, P.

2021
Nature Publishing Group UK [London]

This record in other databases:  

Please use a persistent id in citations: doi:10.1038/s41467-021-26151-9

Abstract: Although several oropharyngeal cancer (OPC) susceptibility loci have been identified, most previous studies lacked detailed information on human papillomavirus (HPV) status. We conduct a genome-wide analysis by HPV16 serology status in 4,002 oral cancer cases (OPC and oral cavity cancer (OCC)) and 5,256 controls. We detect four susceptibility loci pointing to a distinct genetic predisposition by HPV status. Our most notable finding in the HLA region, that is now confirmed to be specific of HPV(+)OPC risk, reveal two independent loci with strong protective effects, one refining the previously reported HLA class II haplotype association. Antibody levels against HPV16 viral proteins strongly implicate the protective HLA variants as major determinants of humoral response against L1 capsid protein or E6 oncoprotein suggesting a natural immune response against HPV(+)OPC promoted by HLA variants. This indicates that therapeutic vaccines that target E6 and attenuate viral response after established HPV infections might protect against HPV(+)OPC.

---

Contributing Institute(s):

1. Infektionen und Krebs-Epidemiologie (F022)
2. Infektionen und Krebs-Epidemiologie (F020)

Research Program(s):

1. 316 - Infektionen, Entzündung und Krebs (POF4-316) (POF4-316)

Appears in the scientific report 2021

---

Database coverage:
; ; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Agriculture, Biology and Environmental Sciences ; Current Contents - Life Sciences ; Current Contents - Physical, Chemical and Earth Sciences ; DOAJ Seal ; Essential Science Indicators ; Fees ; IF >= 10 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection ; Zoological Record

---